Oncology

Carthera kicks off pivotal trial with blood-brain-barrier opening device

Carthera has enrolled the first patient in a pivotal trial evaluating its low-intensity pulsed ultrasound (LIPUS)-based technology which helps drugs…

FDA grants clearance for Hologic’s cervical cancer screening system

The US Food and Drug Administration (FDA) has granted clearance for Hologic’s new Genius Digital Diagnostics System with the Genius…

Delfi launches new assay to monitor cancer treatment

US-based blood-based cancer detection test developer Delfi Diagnostics has introduced the new DELFI-Tumor Fraction (DELFI-TF) assay. DELFI-TF is a fragmentome-based,…

City of Hope, TGen develop new approach for early cancer detection

Researchers from City of Hope in the US and Translational Genomics Research Institute (TGen) have created a machine-learning tool for…

Positive trial results for Orlucent’s handheld melanoma detection device

Orlucent has reported positive results from a study evaluating its handheld point-of-care molecular skin fluorescence imaging (mSFI) system for detecting…

Veracyte acquires C2i Genomics for $95m to boost cancer diagnostics range

US-based Veracyte has agreed to acquire minimal residual disease (MRD) test developer C2i genomics in a deal worth up to…

Zedsen to test electrical sensing device in UK cancer trial

Biosensor company Zedzen has partnered with the Imperial College Healthcare NHS Trust to conduct a clinical study investigating its non-invasive…

Allogene cuts 22% of workforce amid blood cancer therapy pivot

Allogene Therapeutics is discontinuing two of its Phase II trials investigating its ‘off-the-shelf’ cell therapy in advanced large B-cell lymphoma…

AbbVie partners with BigHat to develop antibody therapies

AbbVie has partnered with BigHat Biosciences to identify and develop antibody therapies in oncology and neuroscience indications. As part of…

ABK Biomedical obtains breakthrough designation for microspheres device

ABK Biomedical has received breakthrough device designation (BDD) from the US Food and Drug Administration (FDA) for its Eye90 microspheres…

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close